BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

SHR-8068: trial readouts and FDA decisions

1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-30 est.P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06465563 SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract CancerBiliary Tract Canceractive not recruiting93

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06859775 SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical CancerRecurrent or Metastatic Cervical Cancerrecruiting100
2026-10 est.P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06618664 A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Advanced Hepatocellular Carcinomarecruiting590
2026-08 est.P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07110571 A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ CancerGastric Cancer; Gastroesophageal-junction Cancerrecruiting200
2026-06-30 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05444088 Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular CarcinomaAdvanced Hepatocellular Carcinomaunknown129

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.